215 related articles for article (PubMed ID: 9739487)
21. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism.
Schiavon R; Battaglia P; De Fanti E; Fasolin A; Biasioli S; Targa L; Guidi G
Clin Chim Acta; 2002 Oct; 324(1-2):39-44. PubMed ID: 12204423
[TBL] [Abstract][Full Text] [Related]
22. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity.
Sorenson RC; Bisgaier CL; Aviram M; Hsu C; Billecke S; La Du BN
Arterioscler Thromb Vasc Biol; 1999 Sep; 19(9):2214-25. PubMed ID: 10479665
[TBL] [Abstract][Full Text] [Related]
23. High-density lipoprotein composition and paraoxonase activity in Type I diabetes.
Valabhji J; McColl AJ; Schachter M; Dhanjil S; Richmond W; Elkeles RS
Clin Sci (Lond); 2001 Dec; 101(6):659-70. PubMed ID: 11724654
[TBL] [Abstract][Full Text] [Related]
24. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1.
Deakin SP; James RW
Clin Sci (Lond); 2004 Nov; 107(5):435-47. PubMed ID: 15265000
[TBL] [Abstract][Full Text] [Related]
25. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis.
Shih DM; Gu L; Xia YR; Navab M; Li WF; Hama S; Castellani LW; Furlong CE; Costa LG; Fogelman AM; Lusis AJ
Nature; 1998 Jul; 394(6690):284-7. PubMed ID: 9685159
[TBL] [Abstract][Full Text] [Related]
26. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis?
Heinecke JW; Lusis AJ
Am J Hum Genet; 1998 Jan; 62(1):20-4. PubMed ID: 9443884
[No Abstract] [Full Text] [Related]
27. Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep.
Mackness B; Durrington P; Povey A; Thomson S; Dippnall M; Mackness M; Smith T; Cherry N
Pharmacogenetics; 2003 Feb; 13(2):81-8. PubMed ID: 12563177
[TBL] [Abstract][Full Text] [Related]
28. Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women.
Rantala M; Silaste ML; Tuominen A; Kaikkonen J; Salonen JT; Alfthan G; Aro A; Kesäniemi YA
J Nutr; 2002 Oct; 132(10):3012-7. PubMed ID: 12368388
[TBL] [Abstract][Full Text] [Related]
29. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity.
Costa LG; Richter RJ; Li WF; Cole T; Guizzetti M; Furlong CE
Biomarkers; 2003; 8(1):1-12. PubMed ID: 12519632
[TBL] [Abstract][Full Text] [Related]
30. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation.
Mackness MI; Arrol S; Mackness B; Durrington PN
Lancet; 1997 Mar; 349(9055):851-2. PubMed ID: 9121268
[No Abstract] [Full Text] [Related]
31. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles.
Marathe GK; Zimmerman GA; McIntyre TM
J Biol Chem; 2003 Feb; 278(6):3937-47. PubMed ID: 12466264
[TBL] [Abstract][Full Text] [Related]
32. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?
Mackness M; Mackness B
Free Radic Biol Med; 2004 Nov; 37(9):1317-23. PubMed ID: 15454272
[TBL] [Abstract][Full Text] [Related]
33. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression.
Brophy VH; Jampsa RL; Clendenning JB; McKinstry LA; Jarvik GP; Furlong CE
Am J Hum Genet; 2001 Jun; 68(6):1428-36. PubMed ID: 11335891
[TBL] [Abstract][Full Text] [Related]
34. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism.
Costa LG; Li WF; Richter RJ; Shih DM; Lusis A; Furlong CE
Chem Biol Interact; 1999 May; 119-120():429-38. PubMed ID: 10421480
[TBL] [Abstract][Full Text] [Related]
35. Paraoxonase and atherosclerosis.
Durrington PN; Mackness B; Mackness MI
Arterioscler Thromb Vasc Biol; 2001 Apr; 21(4):473-80. PubMed ID: 11304460
[TBL] [Abstract][Full Text] [Related]
36. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan.
Ko YL; Ko YS; Wang SM; Hsu LA; Chang CJ; Chu PH; Cheng NJ; Chen WJ; Chiang CW; Lee YS
Atherosclerosis; 1998 Dec; 141(2):259-64. PubMed ID: 9862174
[TBL] [Abstract][Full Text] [Related]
37. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients.
Tomás M; Sentí M; García-Faria F; Vila J; Torrents A; Covas M; Marrugat J
Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2113-9. PubMed ID: 10978257
[TBL] [Abstract][Full Text] [Related]
38. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity.
Jaouad L; Milochevitch C; Khalil A
Free Radic Res; 2003 Jan; 37(1):77-83. PubMed ID: 12653220
[TBL] [Abstract][Full Text] [Related]
39. [Human plasma paraoxonase (HuPON1): an anti-atherogenic enzyme with organophosphate hydrolase activity].
Josse D; Masson P
Ann Pharm Fr; 2001 Apr; 59(2):108-18. PubMed ID: 11320335
[TBL] [Abstract][Full Text] [Related]
40. Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in R-allele-carrier but not in QQ homozygous elderly subjects on a tomato-rich diet.
Bub A; Barth S; Watzl B; Briviba K; Herbert BM; Lührmann PM; Neuhäuser-Berthold M; Rechkemmer G
Eur J Nutr; 2002 Dec; 41(6):237-43. PubMed ID: 12474066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
